Arginine

Arginine

SCHEMBL422530

N=C(N)NCCC[C@H](N)C(=O)O.[NaH]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.54
DDAH1 O94760 4/20 0.50
NOS2 P35228 6/20 0.49
NOS1 P29475 6/20 0.49
NOS3 P29474 5/20 0.49
GSR P00390 1/20 0.47
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 2/20 0.46
TSHR P16473 2/20 0.46
GLA P06280 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
KMT2A Q03164 2/20 0.44
ALOX15 P16050 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
MEN1 O00255 1/20 0.43
ARG2 P78540 4/20 0.43
ARG1 P05089 3/20 0.43
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL422529 1.00 OTC (0.54) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL6034083 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL8678605 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL29050239 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL19816040 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL23608085 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL19816043 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL29050238 0.98 OTC (0.53) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL1790 0.98 OTC (0.56) OTCDDAH1NOS2NOS1NOS3
Arginine SCHEMBL6374054 0.98 OTC (0.56) OTCDDAH1NOS2NOS1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116282217-B Ternary positive electrode material precursor, preparation method thereof, positive electrode material and secondary battery 广东佳纳能源科技有限公司 2025-02-11 CN claimed
CN-118452369-A Preparation method of saliva extraction induced liquid of Poecilobdella manillensis 云南云蛭康生物科技有限公司 2024-08-09 CN claimed
CN-118299531-A Modified sodium supplementing nano carbon negative electrode material, preparation method thereof and sodium ion battery 四川启睿克科技有限公司 2024-07-05 CN claimed
CN-113163811-B Sparkling beverage with improved taste quality exhibited by sugar and sweetener 三得利控股株式会社 2024-03-26 CN claimed
CN-113788865-B Method for preparing fructose by catalyzing glucose isomerization through ionic liquid loaded by organic metal framework material 华南理工大学 2024-03-19 CN claimed
WO-2023119100-A1 STABLE PHARMACEUTICAL COMPOSITIONS MANKIND PHARMA LTD. (IN) 2023-06-29 WO claimed
CN-116282217-A Ternary positive electrode material precursor, preparation method thereof, positive electrode material and secondary battery 广东佳纳能源科技有限公司 2023-06-23 CN claimed
US-20230172824-A1 Tooth Densensitizing Oral Care Compositions, Devices And Methods PROCTER & GAMBLE (US) 2023-06-08 US claimed
US-20230055555-A1 METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION Sumitomo Pharma Co., Ltd. (JP) 2023-02-23 US claimed
EP-4074332-A1 METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION Sumitomo Pharma Co., Ltd. (JP) 2022-10-19 EP claimed
US-20140378490-A1 Formulations of Phenyl Uracil Compounds ABBVIE INC. (US) 2014-12-25 US claimed
CN-103768071-A Oral preparation for treating diabetes CHINA STATE INST PHARM IND 2014-05-07 CN claimed
EP-2685964-A1 FORMULATIONS OF PHENYL URACIL COMPOUNDS AbbVie Inc. (US) 2014-01-22 EP claimed
WO-2012129099-A1 FORMULATIONS OF PHENYL URACIL COMPOUNDS ABBOTT LABORATORIES (US) 2012-09-27 WO claimed
US-20110117194-A1 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER HANALL BIOPHARMA CO., LTD. (KR) 2011-05-19 US claimed
CN-102065847-A Pharmaceutical formulation containing angiotensin-II receptor blocker HANALL PHARMACEUTICAL CO LTD 2011-05-18 CN claimed
EP-2281557-A2 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER HanAll Biopharma Co., Ltd. (KR) 2011-02-09 EP claimed
CN-101450059-A Anthelmintic agent and preparation method thereof TIANJIN PACIFIC PHARMACEUTICAL (CN) 2009-06-10 CN claimed
CN-1527701-A Tablets quickly disintegrated in oral cavity ������ҩ��ʽ���� 2004-09-08 CN claimed
CN-1091952-A Cosmetic composition UNILEVER NV (NL) 1994-09-14 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055555-A1 METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION VIP, IWS1, WFS1 OTC 2922/4885DDAH1 3166/4885NOS2 4583/4885
US-20140378490-A1 Formulations of Phenyl Uracil Compounds UNG, UMPS, TYMP OTC 266/4885DDAH1 2062/4885NOS2 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.